UCB Stock Analysis: How Valuable Could Bimzelx Become?

Bimzelx generated €1.52 billion in the first half of 2026 and UCB now expects peak annual sales above €7 billion. The immunology drug could become one of Europe’s most valuable pharmaceutical products—but strong competition, execution risks and a demanding stock-market valuation remain important considerations.

Bimzelx is rapidly transforming UCB from a specialised Belgian biopharmaceutical company into a major global participant in immunology.

The treatment generated €1.52 billion in sales during the first half of 2026, approximately double the previous year’s level. More than 135,000 patients were receiving the drug worldwide by the end of the period.

UCB has consequently increased its peak-sales forecast from its previous target of at least €4 billion to more than €7 billion annually.

If this objective is achieved, Bimzelx could generate more revenue than UCB’s entire product portfolio did only a few years ago. It could also become one of the largest pharmaceutical products ever developed by a European biotechnology company.

However, the market is already assigning substantial value to this opportunity. UCB’s market capitalisation was approximately €43 billion at the end of July 2026, even after the shares fell sharply following the company’s half-year results.

The investment question is therefore not simply whether Bimzelx will become a blockbuster. It already has. The real question is whether sales can move from approximately €3 billion on a current annualised basis toward—and potentially beyond—€7 billion.

What is Bimzelx?

Bimzelx, whose scientific name is bimekizumab, is a monoclonal antibody developed to treat chronic inflammatory diseases.

The treatment selectively inhibits two inflammatory signalling proteins:

Interleukin-17A
Interleukin-17F

These cytokines play an important role in several immune-mediated conditions affecting the skin, joints and spine.

Other established treatments generally inhibit only IL-17A or target different inflammatory pathways. Bimzelx’s ability to block both IL-17A and IL-17F is intended to provide a broader and potentially more powerful therapeutic effect.

The drug is approved in important markets for several conditions:

Moderate-to-severe plaque psoriasis
Psoriatic arthritis
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis
Hidradenitis suppurativa

This collection of indications gives UCB access to several large patient populations using a single biological product.

Bimzelx has already become a major blockbuster

Bimzelx’s commercial acceleration has been exceptional.

Sales reached only €607 million in 2024. They then increased to approximately €2.22 billion in 2025 as UCB expanded the product into additional indications and accelerated its U.S. launch.

During the first half of 2026, the drug generated €1.52 billion. This implies annualised sales above €3 billion, although pharmaceutical sales are not necessarily distributed evenly throughout the year.

The progression can be summarised as follows:

Period	Bimzelx sales
2024	€607 million
2025	€2.22 billion
First half of 2026	€1.52 billion
Current peak-sales target	More than €7 billion

Reaching €7 billion would require the product’s annual revenue to more than double again from its present annualised level.

That is ambitious, but the opportunity is supported by additional patient adoption, a relatively recent U.S. launch and the availability of multiple approved indications.

Why UCB raised the peak-sales target

UCB’s previous official guidance indicated peak annual sales of at least €4 billion.

The new target above €7 billion represents a major increase and reflects greater confidence in several areas.

Stronger U.S. adoption

The United States is the world’s most valuable pharmaceutical market and generally provides higher prices than Europe.

Bimzelx received its first U.S. approval for plaque psoriasis in October 2023. Additional approvals for psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis followed in 2024.

The FDA also approved Bimzelx for moderate-to-severe hidradenitis suppurativa in November 2024.

These approvals give UCB the opportunity to promote a single product across dermatology and rheumatology practices.

Multiple large indications

Bimzelx is not dependent on a single disease.

Psoriasis is a large and established biological-treatment market. Psoriatic arthritis and axial spondyloarthritis provide additional growth, while hidradenitis suppurativa represents an important opportunity because many patients remain inadequately treated.

The ability to address multiple diseases increases the potential patient population and makes UCB’s commercial investment more efficient.

Clinical differentiation

Bimzelx is differentiated by its simultaneous inhibition of IL-17A and IL-17F.

In March 2026, UCB reported results from a head-to-head study in psoriatic arthritis in which Bimzelx outperformed AbbVie’s Skyrizi on the study’s principal measure.

Head-to-head evidence can be commercially valuable because physicians and insurers must choose among several effective biological treatments.

Superior data in one trial does not guarantee complete commercial dominance. However, it can strengthen Bimzelx’s position in treatment guidelines, reimbursement negotiations and prescribing decisions.

A long remaining commercial period

UCB indicates that Bimzelx’s expected loss of exclusivity is approximately:

2035 in the United States
2036 in Europe
2037 in Japan

These dates exclude possible patent-term extensions and remain indicative.

The timeline potentially gives UCB close to a decade to expand the product before biosimilar competition becomes a major threat.

How large is the addressable market?

The global immunology market supports several medicines with annual revenue well above €5 billion.

AbbVie’s Skyrizi generated approximately $5.5 billion in the second quarter of 2026 alone, while Rinvoq contributed around $2.5 billion. Johnson & Johnson’s Tremfya generated approximately $1.6 billion during the first quarter.

These figures cover different combinations of indications and cannot be compared directly with Bimzelx. Nevertheless, they demonstrate that the commercial market for effective immunology medicines is large enough to support multiple multibillion-euro products.

UCB does not need to displace every established competitor to reach €7 billion. It needs to capture a meaningful share across several dermatological and rheumatological diseases.

The most important issue will be whether Bimzelx becomes one of the preferred initial biological treatments or remains more heavily used after patients have failed other therapies.

Earlier placement in the treatment sequence would substantially increase the product’s value.

An illustrative valuation of Bimzelx

A pharmaceutical product cannot be valued simply by multiplying its peak sales by a fixed number. Its value depends on several factors:

Speed of the commercial ramp
Manufacturing and marketing costs
Price and reimbursement
Remaining exclusivity
Taxes
Competition
Additional clinical investment
Sales decline after patent expiry
Appropriate discount rate

Nevertheless, illustrative scenarios help demonstrate the scale of Bimzelx’s potential contribution to UCB.

Scenario	Illustrative peak sales	Possible product value
Conservative	€5 billion	€10–14 billion
Base case	€7 billion	€16–22 billion
Upside case	€9 billion	€22–30 billion

These ranges are not analyst targets or formal valuations. They represent an illustrative discounted value based on different sales trajectories, pharmaceutical operating margins and the remaining period before expected loss of exclusivity.

Under the base case, Bimzelx could reasonably account for around 40% to 50% of UCB’s current enterprise value.

The upper scenario would require strong adoption across all major indications, favourable pricing and limited competitive disruption. The conservative case assumes slower market-share gains, greater pricing pressure or stronger performance from rival treatments.

Could sales exceed €7 billion?

UCB describes its guidance as peak sales of more than €7 billion, meaning €7 billion should not necessarily be interpreted as a maximum.

A path toward €8 billion or €9 billion could become plausible if:

U.S. prescription growth remains strong
Bimzelx secures earlier use in treatment pathways
Head-to-head studies continue to support differentiation
Hidradenitis suppurativa exceeds expectations
Pricing remains resilient
Additional indications are approved
Manufacturing capacity keeps pace with demand
Competing treatments encounter clinical or commercial setbacks

However, peak-sales forecasts in the pharmaceutical industry are highly uncertain. Changes in reimbursement, safety information, physician preferences or competitive products can dramatically alter a medicine’s trajectory.

Bimzelx’s current momentum supports UCB’s confidence, but investors should not automatically assume that sales above €7 billion are guaranteed.

UCB’s first-half performance

UCB reported first-half net sales of approximately €4.09 billion, an increase of 23%.

Adjusted EBITDA reached €1.7 billion, representing growth of 68% and an adjusted EBITDA margin of 40.7%. Core earnings per share nearly doubled to €6.84.

The company raised its 2026 guidance and now expects adjusted EBITDA to grow by a mid-teens to low-twenties percentage at constant exchange rates.

These figures initially appear exceptionally strong. However, part of the first-half earnings performance came from favourable timing and non-recurring contributions.

Other operating income included a substantial contribution from partner-related arrangements, while clinical-development expenditure was relatively low because of project timing.

UCB expects clinical spending to increase during the second half of 2026.

This explains why the shares fell sharply despite the higher guidance.

Why UCB shares initially fell

UCB’s shares dropped more than 8% following the earnings release, falling from approximately €251 to around €217 during the session.

The negative reaction reflected three principal concerns.

First, Bimzelx sales were slightly below analyst expectations, despite almost doubling year over year.

Second, the exceptional first-half EBITDA margin may not be sustainable because research and development expenditure will increase during the second half.

Third, some of the earnings outperformance came from legacy products and non-recurring or timing-related items rather than Bimzelx alone.

The reaction illustrates the high expectations already embedded in UCB’s valuation. Investors are no longer satisfied with strong growth; they expect Bimzelx consistently to meet or exceed increasingly ambitious forecasts.

The stock recovered part of its loss on July 31, trading around €223, but remained well below its 52-week high of €289.50.

UCB’s valuation

At approximately €223 per share, UCB’s market capitalisation was around €43 billion.

Published valuation figures vary because recent earnings include substantial one-off income. Based on consensus forecasts, the stock traded at approximately 24 times forward earnings before the latest estimate revisions.

That is a significant premium to many mature European pharmaceutical companies.

The premium reflects:

Bimzelx’s rapid growth
UCB’s improving margins
A long remaining exclusivity period
Additional growth products
A specialised neuroscience and immunology pipeline

The shares could still appear attractive if Bimzelx exceeds €7 billion and the company converts that revenue into strong recurring cash flow.

However, the valuation becomes more difficult to justify if Bimzelx growth slows below expectations or if research expenditure rises faster than revenue.

Competition represents the largest commercial risk

Bimzelx operates in one of the pharmaceutical industry’s most competitive markets.

Important rivals include:

AbbVie’s Skyrizi and Rinvoq
Novartis’s Cosentyx
Johnson & Johnson’s Tremfya
Eli Lilly’s Taltz
Amgen’s Otezla
Bristol Myers Squibb’s Sotyktu
Several biosimilar versions of older biological products

New treatments are also approaching the market.

Takeda’s oral psoriasis medicine zasocitinib produced positive late-stage results and could offer patients a more convenient alternative to injections. Takeda believes the medicine could eventually generate annual sales of $3 billion to $6 billion.

Bimzelx must therefore continue demonstrating superior efficacy, acceptable safety and competitive value for healthcare systems.

Safety and reimbursement risks

As with other immune-modifying biological treatments, Bimzelx carries safety considerations that physicians must evaluate.

The prescribing information includes warnings and monitoring requirements involving infections and other immune-related complications. Additional safety signals could affect physician confidence or lead regulators to modify the label.

Reimbursement is another important variable.

Health insurers and public healthcare systems increasingly negotiate aggressively over biological-treatment prices. Competition among several effective medicines can produce discounts that reduce revenue even when patient numbers continue growing.

UCB must balance market-share expansion with the preservation of attractive net pricing.

Manufacturing becomes strategically important

Bimzelx’s rapid growth also creates a manufacturing challenge.

Biological medicines are more complex to produce than conventional tablets. UCB needs sufficient manufacturing capacity, reliable quality control and resilient supply chains.

The company announced plans to invest approximately $2 billion in a new biological manufacturing facility near Atlanta, creating around 330 jobs.

The plant will strengthen UCB’s U.S. production footprint and support growing demand for treatments such as Bimzelx. However, construction is expected to take several years.

In the meantime, any manufacturing interruption or capacity limitation could constrain commercial growth.

UCB is preparing for life beyond Bimzelx

Bimzelx is increasingly dominant within UCB’s investment story, but management is trying to prevent the company from becoming dependent on a single product.

Other growth drivers include:

Fintepla for rare epileptic seizures
Rystiggo for generalised myasthenia gravis
Zilbrysq for generalised myasthenia gravis
Evenity for osteoporosis
Briviact for epilepsy

UCB has also agreed to acquire Candid Therapeutics for up to $2.2 billion, strengthening its autoimmune pipeline and providing potential growth beyond Bimzelx’s eventual patent expiry.

These investments are strategically important because the value of every successful pharmaceutical product eventually declines when exclusivity ends.

The bull case for UCB shares

The positive investment thesis is straightforward:

Bimzelx is already a proven multibillion-euro product.
Sales are growing rapidly across several indications.
UCB has raised peak-sales guidance above €7 billion.
U.S. adoption remains at an early stage.
Head-to-head data could support additional market share.
Exclusivity may continue until 2035–2037.
Rising high-margin sales should create substantial operating leverage.
UCB has additional neuroscience and immunology products.

If Bimzelx reaches €7 billion earlier than expected—or ultimately approaches €9 billion—the current valuation could prove conservative.

The bear case

The principal risks are equally significant:

Bimzelx sales were already slightly below high market expectations in the first half.
Competition from Skyrizi, Rinvoq, Tremfya and future oral medicines is intense.
Pricing and reimbursement pressure could limit revenue.
Safety concerns could affect prescribing.
Research and commercial expenditure will increase.
Current profitability benefited from non-recurring and timing-related items.
UCB is becoming increasingly dependent on one product.
The stock still trades at a growth-company valuation.
Biosimilar competition will eventually emerge after exclusivity expires.

The greatest risk may not be a commercial failure. Bimzelx can remain highly successful while still disappointing investors if it fails to reach the very optimistic expectations embedded in UCB’s share price.

What investors should monitor

The most useful indicators for evaluating Bimzelx will include:

Quarterly and half-year sales
Number of patients receiving the treatment
U.S. prescription growth
Market share by indication
Net pricing and reimbursement
Head-to-head clinical results
New indication approvals
Manufacturing capacity
Safety updates
Research and commercial expenditure
UCB’s adjusted EBITDA margin
Revisions to the €7 billion peak-sales target

Investors should pay particular attention to whether Bimzelx’s sales growth remains comfortably above 30% as the revenue base becomes larger.

Final assessment: Bimzelx could be worth €16–22 billion

Bimzelx has progressed from a promising clinical asset into one of Europe’s most commercially important new medicines.

Its €1.52 billion of first-half sales, broad collection of approved indications and long remaining exclusivity support UCB’s expectation that annual revenue can exceed €7 billion.

Under a reasonable base-case commercial scenario, Bimzelx could have an illustrative product value of approximately €16 billion to €22 billion. A more optimistic outcome involving peak sales close to €9 billion could push that value toward €30 billion.

That would make Bimzelx responsible for a substantial share of UCB’s current €43 billion market capitalisation.

The opportunity is therefore considerable—but so are expectations.

UCB’s sharp post-results decline demonstrated that investors now demand near-perfect execution. Bimzelx must not only grow; it must repeatedly surpass forecasts while preserving pricing, margins and clinical differentiation.

The stock could offer long-term value if Bimzelx becomes a €7 billion-plus franchise and UCB develops additional products for the period beyond 2035. But investors should recognise that the shares already reflect a considerable part of that success.

Market figures reflect information available on July 31, 2026. The valuation scenarios are illustrative and do not constitute price targets or investment advice.